There is a tremendous amount of progress being made in AML. It was remarkable to see the significant work being done in the field of AML at the recent American Society of Hematology (ASH) conference in Atlanta in December 2021.
AML expert and Director of the Program for Drug Development in Leukemia at Memorial Sloan Kettering, Dr. Eytan Stein, will share the top AML research of 2021 that was presented by himself and his colleagues at the 2021 ASH conference. He will cover a breadth of topics such as treatment options in the newly diagnosed and relapsed setting, what's been learned about maintenance therapy and MRD status, how COVID-19 is affecting AML patients and the advancements of various immunotherapies. Dr. Stein will summarize topics to consider at each phase of AML in a clear and concise way. He will end by providing us his thoughts on what AML advancements and research to look out for in 2022.
Katie joined the HealthTree Foundation as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.
Hematologist Oncologist, Director of the Program for Drug Development in Leukemia at MSKCC
Thank you for your interest in the event. If you have any question, we would love to help! Just fill out the form below and we will get back to you as quickly as possible.